ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2010
Interleukin-13: prospects for new treatments.
Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Interleukin-13 -1112 C/T promoter polymorphism confers risk for COPD: a meta-analysis.PloS one · 2013Pooled it
- Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood Framework.CPT: pharmacometrics & systems pharmacology · 2026Trial
- Article
- The Importance of Lung Innate Immunity During Health and Disease.Pathogens (Basel, Switzerland) · 2025Review
- Polygoni Multiflori Radix Praeparata polysaccharides enhance gut health and mitigate ischemic stroke by regulating SCFA and amino acid metabolism in gut microbiota.Frontiers in pharmacology · 2025Article
- The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis.Frontiers in medicine · 2023Review
- Critical Players and Therapeutic Targets in Chronic Itch.International journal of molecular sciences · 2022Review
- Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases.Future medicinal chemistry · 2022Review
- Article
- Targeted therapy in eosinophilic chronic obstructive pulmonary disease.ERJ open research · 2021Review
- Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets.Frontiers in physiology · 2021Review
- Systemic Cytokine Profiles of CD4+ T Lymphocytes Correlate with Clinical Features and Functional Status in Stable COPD.International journal of chronic obstructive pulmonary disease · 2020Article
- Intranasal administration ofExperimental and therapeutic medicine · 2019Article
- Variation in doses and duration of particulate matter exposure in bronchial epithelial cells results in upregulation of different genes associated with airway disorders.Toxicology in vitro : an international journal published in association with BIBRA · 2018Article
- Overexpression of miR-155-5p Inhibits the Proliferation and Migration of IL-13-Induced Human Bronchial Smooth Muscle Cells by Suppressing TGF-β-Activated Kinase 1/MAP3K7-Binding Protein 2.Allergy, asthma & immunology research · 2018Article
- Association of Air Pollution Exposure and Interleukin-13 Haplotype with the Risk of Aggregate Bronchitic Symptoms in Children.EBioMedicine · 2018Article
- A novel anti-IL4Rα nanoparticle efficiently controls lung inflammation during asthma.Experimental & molecular medicine · 2016Article
- Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease.Therapeutic advances in chronic disease · 2016Review
- Neurotrophic tyrosine kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 involved in allergic inflammation.Mucosal immunology · 2015Article
- Key mediators in the immunopathogenesis of allergic asthma.International immunopharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
IL-13 is a T-helper type 2 cytokine. Animal models have implicated IL-13 as a critical cytokine in the development of asthma and chronic obstructive pulmonary disease (COPD). In vitro IL-13 exerts important effects on both structural and inflammatory cells within the airway and has the capacity to drive the clinical features of airways disease. In asthma, this view is strongly supported by associations with IL-13 genetic polymorphisms and increased mRNA and protein expression in blood, sputum and bronchial submucosa. In particular, IL-13 up-regulation is associated with severe disease. Current evidence in COPD is conflicting, with some reports supporting and others refuting a role for IL-13. Early clinical trials of anti-IL-13 therapies in asthma have shown promise, and the results of further efficacy studies are eagerly awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.